Scottish Medicines Consortium
Providing advice about the status of all newly licensed medicines
www.scottishmedicines.org.uk
Delta House (8th floor) 50 West Nile Street Glasgow G1 2NP Tel 0141 225 6999 Chairman Professor Kenneth R Paterson
NHS SCOTLAND

levetiracetam 100mg/ml oral solution (Keppra®) (No: 661/10)
UCB Pharma Ltd

17 December 2010

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

levetiracetam 100mg/ml oral solution (Keppra®) is accepted for restricted use within NHS Scotland.

Indication under review: adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in children and infants from 1 month of age to 4 years with epilepsy.

SMC restriction: to initiation and management under the supervision of a paediatric neurologist.

The Scottish Medicines Consortium has previously accepted this product for use within NHS Scotland as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in children from 4 years of age with epilepsy.

Addition of levetiracetam to existing anticonvulsant therapy has shown a greater reduction in partial seizure frequency than addition of placebo.

Levetiracetam is listed in the British National Formulary for Children 2010-2011 for adjunctive treatment for partial seizures with or without secondary generalisation from 1 month old.

Smaller syringe sizes of 1 and 3 ml have been made available to accommodate the smaller volumes for younger children.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including **12 October 2010.**

Chairman
Scottish Medicines Consortium

Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP
Telephone 0141 225 6989
E-mail: rosie.murray@nhs.net

Chairman Professor Kenneth R Paterson